[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Cheng-Kung University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":603},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,41,0,25,[9,42,61,90,117,145,164,184,205,232,259,281,305,328,348,376,395,419,447,470,497,519,544,562,581],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100645111","endoscopic-application-of-hemostatic-drug-powder-in-lower-gastrointestinal-bleeding-a-pilot-study-100645111",false,"NCT07679139","Endoscopic Application of Hemostatic Drug Powder in Lower Gastrointestinal Bleeding: A Pilot Study","Inclusion Criteria:\n\n* patients suspect lower gastrointestinal bleeding\n\nExclusion Criteria:\n\n* absence of indication for endoscopic hemostasis\n* known allergy to sucralfate, TXA\n* presence of a hollow organ perforation","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","This clinical trial will enroll patients at National Cheng Kung University Hospital. All patients who are hospitalized for lower gastrointestinal bleeding and undergo colonoscopy will be invited to participate. This study uses random allocation, with one Intervention group and one Standard group. Both groups will receive standard endoscopic hemostasis. Afterward, patients in the Intervention group will receive local administration of 1.5 g of tranexamic acid and 3 g of sucralfate. Following the endoscopic procedure, patients will be directly observed for 5 minutes to confirm successful hemostasis. All patients will be followed for 28 days to assess the occurrence of post-procedural rebleeding.",[26],"Bleeding After GI Endoscopy",[28,29,30],"lower gastrointestinal bleeding","tranexamic acid","sucralfate","NOT_YET_RECRUITING","2026-06-25",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":34,"type":20},{"date":38,"type":20},"2027-12-31",{"name":40,"class":41},"National Cheng-Kung University Hospital","OTHER",{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":59,"leadSponsor":60,"locationsCount":4},"100645178","topical-application-of-sucralfate-in-promoting-healing-of-esophageal-ulcers-after-esophageal-varices-ligation-a-randomized-controlled-trial-100645178","NCT07679191","Topical Application of Sucralfate in Promoting Healing of Esophageal Ulcers After Esophageal Varices Ligation: A Randomized Controlled Trial","Inclusion Criteria:\n\n* cirrhotic patients aged ≥ 18 years who accept endoscopy for esophageal variceal bleeding\n\nExclusion Criteria:\n\n* no need of endoscopic hemostasis\n* allergy to sucralfate\n* other etiology of bleeding than EV bleeding",{"count":19,"type":20},[23],"Patients with EV bleeding often suffered from hematemesis, Tarry stool, and blood loss. Standard treatment for bleeding esophageal varices includes hemodynamic stabilization, pharmacological control, and endoscopic intervention. For endoscopic intervention, endoscopic variceal ligation (EVL) is the first-line therapy with 95% initial hemostasis success rate. However, after variceal ligation, esophageal ulcers form 3 days later. These ulcers expose underlying vessels in friable esophageal mucosa, exacerbated by portal hypertension and coagulopathy in cirrhosis patients. Bleeding peaks around day 5-10 when bands detach. Among these patients, 7-9% of patients experience recurrent bleeding as a result. Recurrent bleeding from esophageal ulcers carries an extremely high mortality rate, particularly in patients with advanced stage cirrhosis. Therefore, how to promote esophageal ulcer healing and prevent ulcer rebleeding is an important clinical issue.\n\nProton pump inhibitors (PPIs) are the primary drugs for preventing and treating gastric ulcers, but clinical evidence for their role in preventing post-ligation esophageal ulcers is insufficient. Sucralfate, a complex of aluminum hydroxide and sucrose octa sulfate, can bind to the wound base. This protective barrier can prevent the wound from further environmental injury. Sucralfate has been widely used for wounds and ulcer treatment, e.g., skin wounds, oral ulcers, and peptic ulcers. Our recent clinical trial also proved topical sucralfate can prevent postpolypectomy bleeding. Therefore, this study aimed to investigate whether the topical administration of sucralfate after standard endoscopic hemostasis can promote the esophageal ulcer healing and reduce the rebleeding event.",[52],"Ulcer Healing",[54,55,56],"Esophageal varices","Post-ligation ulcer","Sucralfate",{"date":34,"type":35},{"date":34,"type":20},{"date":38,"type":20},{"name":40,"class":41},{"id":62,"slug":63,"hasResults":12,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":12,"sex":16,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":72,"studyType":73,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},"100641165","an-ai-based-prediction-of-cognitive-capacity-in-older-adults-and-individuals-with-mild-cognitive-impairment-during-virtual-reality-driving-tasks-100641165","NCT07656389","An AI-Based Prediction of Cognitive Capacity in Older Adults and Individuals With Mild Cognitive Impairment During Virtual Reality Driving Tasks","From Eye Movements to Visuomotor Coupling: An AI-Based Prediction of Cognitive Capacity in Older Adults and Individuals With Mild Cognitive Impairment During Virtual Reality Driving Tasks","Inclusion Criteria:\n\n* (1) a score of 23 or higher on the Montreal Cognitive Assessment; (2) a Clinical Dementia Rating score of 0 for cognitively healthy participants or 0.5 for participants with mild cognitive impairment (MCI); (3) healthy young adults aged between 30 and 39 years, and cognitively healthy older adults and participants with MCI aged between 65 and 85 years; (4) right-hand dominance; and (5) adequate visual function to complete VR and eye-tracking tasks, defined as corrected binocular visual acuity of at least 0.5 without severe visual field deficits.\n\nExclusion Criteria:\n\n* (1) the presence or history of major psychiatric disorders or central nervous system diseases; (2) significant ocular diseases, such as untreated cataracts, active retinal diseases, moderate-to-severe or poorly controlled glaucoma, or marked visual field deficits beyond a specified level; (3) epilepsy; and (4) severe dizziness or VR-induced motion sickness.","30 Years","85 Years",{"count":71,"type":20},192,"12 Months","OBSERVATIONAL","Driving ability in older adults is essential for independent mobility and social participation, yet declines under high cognitive load or distraction often lead to visual attention failures such as \"look-but-fail-to-see,\" increasing crash risk. Older adults and individuals with mild cognitive impairment (MCI) show impairments in visual attention, executive control, and visuomotor integration, which are not adequately captured by conventional assessments. Virtual reality (VR) integrated with eye-tracking and upper-limb motion analysis enables ecologically valid simulation of driving scenarios and precise quantification of visuomotor behavior. However, current studies are limited by single-scenario designs, unimodal AI models, and insufficient integration of action-related data.\n\nThis study proposes a multi-phase framework: Year 1 develops an eye-movement-based AI model for MCI identification; Year 2 integrates multimodal data in VR driving tasks; and Year 3 establishes an explainable AI system with longitudinal validation. The study aims to advance cognitive assessment and develop a digital tool for early MCI detection and driving risk prediction.",[76,77,78,79,80],"Mild Cognitive Impairment (MCI)","Virtual Reality","Eye Movement Disorder","Multimodal Monitoring","Older Adults","2026-06-14",{"date":83,"type":35},"2026-06-18",{"date":85,"type":20},"2026-06-20",{"date":87,"type":20},"2029-12-31",{"name":40,"class":41},1,{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":16,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":116,"locationsCount":89},"100633363","virtual-reality-mirror-therapy-with-focused-object-directed-attention-system-100633363","NCT07525713","Virtual Reality Mirror Therapy With Focused Object-Directed Attention System","Virtual Reality Mirror Therapy With Focused Object-Directed Attention for Neuro-Rehabilitation","Inclusion Criteria:\n\n* Clinical diagnosis of stroke with unilateral side involved;\n* A score of Mini-mental state examination greater than 24 for proving higher mental function;\n* Time of onset \\> 6 months before treatment begins;\n* Premorbid right-handedness.\n\nExclusion Criteria:\n\n* Severe vision impairment;\n* Major cognitive-perceptual deficit;\n* Other brain disease.",true,"20 Years","80 Years",{"count":101,"type":20},54,[23],"In this study, the investigators hypothesized that Virtual Reality Mirror Therapy with Focused Object-Directed Attention (VRMTFOA) would yield superior therapeutic effects compared to conventional Virtual Reality Mirror Therapy (VRMT) in individuals with unilateral stroke.\n\nThe aim of this study is to compare the immediate effects of a single session of VRMT, VRMTFOA, and VRMTFOA with auditory feedback on upper extremity function and brain activity in stroke patients.",[105,106,77,107,108,109],"Stroke","Rehabilitation","Mirror Movement Therapy","Attention","Task Performance","RECRUITING",{"date":112,"type":35},"2026-06-16",{"date":114,"type":35},"2026-04-20",{"date":38,"type":20},{"name":40,"class":41},{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":16,"minAge":98,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":129,"conditions":130,"keywords":134,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":89},"100542278","phase-2-neurotransmitters-in-treatment-resistant-schizophrenia-patients-with-add-on-sodium-benzoate-100542278","NCT06340789","Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate","Functional Connectivity and Associated Neuropeptides Variations in Treatment Resistant Schizophrenia Patients: Treatment Efficacy of add-on Sodium Benzoate","Inclusion Criteria:\n\n1. Fulfil the DSM5 criteria for schizophrenia or schizoaffective disorder\n2. Research criteria for treatment resistance: little or no symptomatic response to multiple (at least two) antipsychotic treatment of an adequate duration (at least 6 weeks) and adequate doses (equivalent to at least 600 milliequivalent (meq)\u002Fday of chlorpromazine)\n3. 6 month period without remission (i.e. ≥4 item-score for the positive symptoms on PANSS scale , especially delusional thoughts, conceptual disorganisation, excitements, grandiosity, hallucinatory behaviour, excitement, persecution, and hostility)\n4. The persistence of illness was defined as a score of ≥4 (moderately ill) on the severity of illness subscale of the Clinical Global Impression scale (CGI-S), and a lack of stable period of good social occupational function.\n\nExclusion Criteria:\n\n1. Current or previous diagnosis of concurrent DSM-5 disorder due to active medical problems, known neurological disease, or a contraindication to MRI scanning\n2. Current diagnosis of substance-related disorder\n3. Any acute or chronic medical condition\n4. History of head trauma or neurological diseases.","55 Years",{"count":126,"type":20},90,[128],"PHASE2","Although antipsychotic is effective for schizophrenia, however, still certain proportion of patients were not responsive to treatment. Treatment resistant schizophrenia (TRS) is accompanied by function decline and heavy burden. In recent decades, the biological mechanism of schizophrenia extended from dopamine theory to the role of glutamate system. This shift could be an alternative pathway to developing the treatment of TRS. Sodium benzoate (SB) could be an option as a glutamatergic agent for the patients with TRS. However, most evidence of SB is for treating patients with schizophrenia and other mental disorders but the evidence for treating patients with TRS is scarce. To predict the treatment response of SB will be an urgent topic in the future. Little is known about the precise medicine for treating patients with TRS. The present project will extend our pilot randomized clinical trial on SB for TRS. A total of 90 patients with TRS will be enrolled from three centers and will be assigned to 8 weeks of treatment with SB or placebo (2:1). A comprehensive battery of potential markers will be employed, including 1H- magnetic resonance spectroscopy (MRS), brain functional connectivity, genotyping, immune biomarkers, cognitive function, and clinical characteristics. The efficacy of SB on TRS will be confirmed in this project. Predictors for treatment response will be identified. Artificial intelligence algorithms will be used for probing the feasibility of precision medicine.",[131,132,133],"Symptom, Cognitive","Schizophrenia","Schizo Affective Disorder",[135,136,137,138],"schizophrenia","sodium benzoate","cognition","treatment resistant schizophrenia",{"date":112,"type":35},{"date":141,"type":35},"2021-11-18",{"date":143,"type":20},"2028-04-30",{"name":40,"class":41},{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":152,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":163,"locationsCount":89},"100634464","endoscopic-application-of-tranexamic-acid-and-sucralfate-in-gastrointestinal-tumor-bleeding-a-randomized-controlled-trial-100634464","NCT07540026","Endoscopic Application of Tranexamic Acid and Sucralfate in Gastrointestinal Tumor Bleeding: A Randomized Controlled Trial","Inclusion Criteria:\n\n* patients aged ≥ 18 years who accept endoscopy for upper GI tumor bleeding\n\nExclusion Criteria:\n\n* patients with no need for endoscopic hemostasis, allergy to sucralfate, tranexamic acid, pregnancy, and patients with hollow organ perforation",{"count":19,"type":20},[23],"Background Gastrointestinal bleeding is a common disease among the population in Taiwan, with gastrointestinal tumor bleeding accounting for 3-5% of cases. The pathophysiology of gastrointestinal tumor bleeding is unique, involving fragile surface mucosa, abnormal vascular proliferation, and malformation, making endoscopic hemostasis challenging. Conventional endoscopic hemostasis methods such as hemostatic injections, clips, or thermal coagulation have suboptimal success rates below 80%, with recurrence rates exceeding 50%. Recent clinical trials have demonstrated that hemostatic powder spraying effectively enhances hemostasis for gastrointestinal ulcers and reduces recurrence rates. Our previous research repurposed tranexamic acid in a powder form to enhance hemostasis for peptic ulcer and applied sucralfate powder to prevent postpolypectomy wound bleeding.\n\nStudy aim Our research team combines previous experience by using tranexamic acid and sucralfate drug powders to spray onto bleeding gastrointestinal tumors to achieve hemostatic effects. Additionally, tumor-derived exosomes are associated with tumor angiogenesis and growth, so we hypothesize that gastrointestinal tumor bleeding may be linked to VEGF and miR-21 expression within gastrointestinal tumor exosomes.\n\nStudy method This study is a clinical randomized controlled trial conducted at National Cheng Kung University Hospital. We will recruit 60 patients with gastrointestinal tumor bleeding undergoing endoscopic hemostasis. Patients in the experimental treatment group will receive additional topical administration of 1.5 g of tranexamic acid and 3 g of sucralfate drug powder. Immediate hemostasis and 30-day bleeding recurrence will be observed. Enrolled patients will also provide blood and tumor specimens for exosome analysis, evaluating the predictive effect of extracted tumor exosomes' VEGF and miR-21 on bleeding risk. This study will explore the association between specific tumor exosome expression levels and bleeding, serving as a basis for bleeding risk assessment and innovative therapies.",[26],[156,157],"Gastric tumor","Tumor bleeding","2026-04-13",{"date":114,"type":35},{"date":161,"type":20},"2026-05-01",{"date":38,"type":20},{"name":40,"class":41},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":97,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":171,"targetDuration":4,"studyType":21,"phases":173,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":89},"100603658","effects-of-virtual-reality-multisensory-cooperative-task-oriented-mirror-therapy-100603658","NCT07139379","Effects of Virtual Reality Multisensory Cooperative Task-Oriented Mirror Therapy","Virtual Reality Multisensory Cooperative Task-Oriented Mirror Therapy for Neuro-Rehabilitation","Inclusion Criteria:\n\n* Clinical diagnosis of stroke with unilateral side involved;\n* A score of Mini-mental state examination greater than 24 for proving higher mental function\n* Time of onset \\> 6 months before treatment begins; and\n* Premorbid right-handedness.\n\nExclusion Criteria:\n\n* Severe vision impairment;\n* Major cognitive-perceptual deficit;\n* Other brain disease.",{"count":172,"type":20},44,[23],"In the proposed study, the investigators assumed that Virtual Reality-Based Generative Bimanual Cooperative Task-Oriented Therapy (VRMCTOMT) will provide a better treatment effects than traditional virtual reality mirror therapy (VRMT) for the patients with unilateral stroke. The aim of the study is to examine the difference in the treatment effects among the combination of task-oriented training with either VRMCTOMT, or VRMT on the upper extremity function and brain activity of the stroke patients.",[105,106,77,107,109],"2026-04-12",{"date":178,"type":35},"2026-04-15",{"date":180,"type":35},"2025-06-24",{"date":182,"type":20},"2026-12-31",{"name":40,"class":41},{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":16,"minAge":98,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":21,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":89},"100528582","phase-2-total-neoadjuvant-therapy-in-rectal-cancer-100528582","NCT06162650","Total Neoadjuvant Therapy in Rectal Cancer","A Phase II Study of Total Neoadjuvant Therapy in Rectal Cancer","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of adenocarcinoma of the rectum;\n* Tumors located at mid or low rectum (distal extension less than 10 cm from the anal verge);\n* Clinical stage II or III (T3\u002F4 and\u002For N+; no distant metastasis);\n* No prior chemotherapy, radiotherapy or surgery for rectal cancer;\n* Age ≥20;\n* ECOG 0-1;\n* Adequate organ function, including followings:\n\nANC ≥1,500\u002FμL; Hb ≥8.0 gm\u002FdL; Platelet 100,000\u002Fmm3; Total bilirubin ≤1.5x upper normal limit; AST ≤3x upper normal limit; ALT ≤3x upper normal limit; Creatinine ≤1.5x upper normal limit;\n\n* Ability to understand and the willingness to sing a written informed consent.\n\nExclusion criteria\n\n* Recurrent rectal cancer;\n* Patients who have concomitant malignancies, except for adequately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix. Subjects who have prior malignancies and have been disease-free for more than 5 years can be enrolled;\n* Patients who have received prior pelvic radiotherapy;\n* Patients with active infection requiring intravenous antibiotic treatment;\n* Patients with a history of any arterial thrombotic event within the past 6 months, including unstable angina, myocardial infarction (MI) or cerebrovascular accident (CVA), New York Hear Association (NYHA) grade II or greater congestive heart failure, or uncontrolled cardiac arrhythmia;\n* Patients with any other concurrent medical or psychiatric condition or disease which, in the investigator's judgement, would make them inappropriate candidates for entry into this study;\n* Women who are pregnant or breastfeeding. Women of childbearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period;\n* Patients receiving other anticancer or experimental therapy;\n* Known DPD deficiency or hypersensitivity to oxaliplatin;\n* Any contraindications to MRI.",{"count":192,"type":20},42,[128],"In this phase 2 study, the efficacy of total neoadjuvant therapy in Taiwanese patients with rectal cancer will be investigated. Patients with stage II or III middle\u002Flow rectal cancer will be prospective enrolled. The total neoadjuvant therapy with the short-course radiotherapy (5×5 Gy over a maximum of 8 days) followed by chemotherapy with mFOLFOX6 for 9 cycles will be administered. The primary endpoint is the complete response (CR) rate which will take into account the patients with clinical and pathological complete response.",[196],"Rectal Cancer","2026-04-07",{"date":199,"type":35},"2026-04-08",{"date":201,"type":35},"2023-11-16",{"date":203,"type":20},"2030-11-16",{"name":40,"class":41},{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":212,"targetDuration":4,"studyType":21,"phases":214,"briefSummary":215,"conditions":216,"keywords":218,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":89},"100621334","continuous-cervical-erector-spinae-plane-block-versus-interscalene-nerve-block-in-shoulder-arthroscopic-surgery-100621334","NCT07369271","Continuous Cervical Erector Spinae Plane Block Versus Interscalene Nerve Block in Shoulder Arthroscopic Surgery","Continuous Cervical Erector Spinae Plane Block Versus Interscalene Nerve Block in Shoulder Arthroscopic Surgery- A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patients scheduled for elective shoulder arthroscopic surgery\n\nExclusion Criteria:\n\n* Contraindications to regional analgesia\n* BMI \\>40\n* ASA physical status IV\n* history of drug or opioid abuse\n* preoperative upper limb motor impairment\n* postoperative ventilator support or ICU admission\n* Inability to provide self-reported pain assessments",{"count":213,"type":20},165,[23],"Shoulder arthroscopic surgery is associated with moderate to severe postoperative pain, which may hinder early mobilization and functional recovery. Interscalene block (ISB) is commonly used to provide effective analgesia but is frequently associated with hemidiaphragmatic paralysis due to phrenic nerve involvement. Cervical erector spinae plane block (ESPB) has been proposed as an alternative regional technique that may provide analgesia while reducing respiratory-related adverse effects. This randomized controlled trial aims to compare the analgesic efficacy and safety of cervical ESPB versus continuous ISB in patients undergoing shoulder arthroscopic surgery.",[217],"Shoulder Arthroscopy",[219,220,221,222,223],"Shoulder arthroscopy","postoperative pain","regional anesthesia","interscalene block","erector spinae plane block","2026-01-17",{"date":226,"type":35},"2026-01-27",{"date":228,"type":20},"2026-01-15",{"date":230,"type":20},"2028-01-31",{"name":40,"class":41},{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":97,"sex":16,"minAge":17,"maxAge":239,"enrollmentInfo":240,"targetDuration":4,"studyType":21,"phases":242,"briefSummary":243,"conditions":244,"keywords":247,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":89},"100619158","effectiveness-of-the-safe-haven-application-app-among-undergraduates-100619158","NCT07340983","Effectiveness of the Safe Haven Application (App) Among Undergraduates","The Effectiveness of the Safe Haven APP on Mental Health Among Undergraduates: A Randomized Controlled Trial","Inclusion Criteria:\n\n* registered undergraduates aged 18-24 years\n* own a personal smart device (mobile phone or tablet)\n* ability to read Chinese\n* willingness to install the study app and complete the follow-up assessments.\n\nExclusion Criteria:\n\n* are on leave of absence or not officially enrolled during the study period\n* are participating in another mental health intervention program or using similar mental health apps.","24 Years",{"count":241,"type":20},68,[23],"The goal of this randomized controlled trial is to evaluate the effectiveness of the Safe Haven app in reducing mental health symptoms and enhancing mental health literacy in undergraduates at a national university in southern Taiwan. The main questions it aims to answer are:\n\nDoes the Safe Haven app lead to significantly greater reductions in general psychological distress, depression, anxiety, and stress compared to standard campus care?\n\nDoes the app result in greater improvements in mental health literacy among participants?\n\nResearchers will compare an experimental group (receiving the Safe Haven app in addition to standard campus care) to a waitlist control group (receiving standard campus care only) to see if the intervention provides superior improvements in mental health outcomes over time.\n\nParticipants will:\n\nComplete online assessments at three time points: baseline (T0), post-intervention (3 months, T1), and follow-up (3 months post-intervention, T2).\n\nExperimental Group: Download the Safe Haven app to complete daily mood self-monitoring and weekly assessments, and receive psychoeducational content, personalized suggestions for 3 months.\n\nControl Group: Maintain access to standard campus care and receive access to the app after the final follow-up assessment.",[245,246],"Depression","Anxiety",[248,249,250,251],"undergraduates","mental health","app","mental health literacy",{"date":253,"type":35},"2026-01-21",{"date":255,"type":35},"2025-09-16",{"date":257,"type":20},"2027-01-31",{"name":40,"class":41},{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":97,"sex":16,"minAge":266,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":21,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":89},"100373093","the-effect-of-iot-based-smart-exercises-system-in-the-senior-adults-100373093","NCT04137939","The Effect of IoT-based Smart Exercises System in the Senior Adults","Smart Health Care and Innovative Technology Service Model Plan : Development of Innovative Health Promotion System for Senior Adults","Inclusion Criteria:\n\n* Adult over 50 years old\n* No significant limb disability or joint deformation\n* No history of cardiovascular disease\n* Never lost balance due to dizziness in the past 12 months\n\nExclusion Criteria:\n\n* limb disability or joint deformation\n* history of cardiovascular disease\n* lost balance due to dizziness in the past 12 months\n* cognitive deficits","50 Years",{"count":268,"type":20},400,[23],"Subjects are divided into two groups, (1) Control (Ctrl) and (2) Smart Exercise (SE) group. Ctrl group are instructed to maintain their daily life. SE participants are instructed to do exercise with smart exercise system twice per week for 12 weeks. The physical fitness tests and questionnaire of both group are performed before and after the 12-week exercise program.",[272],"Elderly Exercise","2025-12-17",{"date":275,"type":35},"2025-12-24",{"date":277,"type":35},"2019-07-15",{"date":279,"type":20},"2027-08-31",{"name":40,"class":41},{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":21,"phases":289,"briefSummary":291,"conditions":292,"keywords":293,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":304,"locationsCount":4},"100612772","phase-4-prevention-of-delayed-post-polypectomy-bleeding-by-endoscopic-sucralfate-spray-in-high-risk-patients-a-randomized-controlled-trial-100612772","NCT07257926","Prevention of Delayed Post-polypectomy Bleeding by Endoscopic Sucralfate Spray in High-risk Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* patients who take antiplatelets or anticoagulants with large polyps (size ≥ 1 cm)\n\nExclusion Criteria:\n\n* lacked complete data (serum creatinine, platelet count, and prothrombin time) pertaining to the previous 6 months\n* those who did not discontinue or inadequately discontinued antiplatelet agents or anticoagulants\n* those who had a known allergy to sucralfate",{"count":288,"type":20},160,[290],"PHASE4","Background： Colonoscopy can detect colon polyps and perform excision to the polyps to prevent colon cancer. However, delayed polypectomy bleeding is one of the complications to be noticed, which has an occurrence rate of about 1-2%, especially large polyps over 1cm with hot snare polypectomy. Colonoscopic clipping was applied for the treatment of bleeding. However, prophylactic clipping after polypectomy was not proved to reduce the rate of delayed polypectomy bleeding. Sucralfate is used for peptic ulcer treatment, which can become a protective layer on the wound to prevent environmental injury. Our preliminary data revealed the endoscopic sucralfate spray could reduce the delayed bleeding rate among general populations. Whether sucralfate can prevent polypectomy wounds from delayed bleeding in high-risk polyps is unknown.\n\nAim： This study aimed to compare the efficacy in reducing delayed bleeding rate between sucralfate administration and prophylactic clipping on high-risk polypectomy wounds.\n\nMethod： This is a randomized clinical trial. The study will recruit 160 patients. After randomization, 80 patients will be classified into the Sucralfate group and 80 into the Clipping group. The participants will receive an endoscopic survey as routine, and we will enroll all patients who take antiplatelets or anticoagulants with polyp size ≥ 1 cm after hot snare polyp excision. Exclusion criteria include patients with an allergy to sucralfate. If immediate polypectomy bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine, heater probe coagulation, and\u002For hemoclipping. After then, we will spray 3g of sucralfate powder through colonoscopy precisely on the polypectomy wound in the Sucralfate group, and prophylactic clipping will be placed on the polypectomy wound in the Clipping group. All enrolled patients will be monitored for delayed bleeding for 28 days after the colonoscopy.\n\nExpected results and clinical importance:\n\nThis study is expected to find that the use of sucralfate powder can more effectively reduce the bleeding risk in high-risk wounds compared to prophylactic clips. In addition to promoting the implementation of national health policies and reducing public exposure to the risk of complications, it can also help avoid medical expenses resulting from complications.",[26],[294,30,295,296,297],"polypectomy","antiplatelet","anticoagulant","postpolypectomy bleeding","2025-12-01",{"date":300,"type":35},"2025-12-02",{"date":302,"type":20},"2025-12-15",{"date":38,"type":20},{"name":40,"class":41},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":97,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":21,"phases":314,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":89},"100599328","phase-4-precise-endoscopic-application-of-nitroglycerin-in-preventing-post-ercp-pancreatitis-100599328","NCT07083063","Precise Endoscopic Application of Nitroglycerin in Preventing Post-ERCP Pancreatitis","Precise Endoscopic Application of Nitroglycerin in Preventing Post-ERCP Pancreatitis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Eligible participants include patients aged ≥ 18 years who accept ERCP and sphincterotomy for common bile duct (CBD) stone extraction.\n\nExclusion Criteria:\n\n* patients with pancreatic cancer\n* shock status (systolic blood pressure \\\u003C 90 mmHg or using inotropic agents)\n* allergy to NTG\n* angle-closure glaucoma\n* severe anemia\n* patients on PDE 5 inhibitors",{"count":313,"type":20},440,[290],"Endoscopic retrograde cholangiopancreatography (ERCP) is a technically demanding procedure combining endoscopy and fluoroscopy to diagnose and treat pancreaticobiliary disorders such as bile duct stones, strictures, and cholangitis. Despite its therapeutic value, ERCP carries a relatively high complication risk of about 10%, with severe complications occurring in roughly 24% of those affected and mortality rates between 0.2% and 0.7%. The most common and significant complication is post-ERCP pancreatitis (PEP), occurring in 2% to 10% of average patients and up to 40% or higher in high-risk groups. PEP ranges from mild, self-limiting inflammation to severe, life-threatening conditions including pancreatic necrosis and multi-organ failure.\n\nPEP arises from mechanical trauma, hydrostatic injury, chemical irritation, or infection during ERCP that activates inflammatory pathways within the pancreas. Key patient-related risk factors include young age, female sex, prior pancreatitis, and sphincter of Oddi dysfunction; procedural factors include difficult biliary cannulation, pancreatic duct manipulation, and precut sphincterotomy.\n\nPreventive strategies focus on minimizing mechanical injury and pharmacologic prophylaxis. Rectal NSAIDs (indomethacin, diclofenac) administered immediately before ERCP are well-supported for reducing PEP risk. Periprocedural aggressive intravenous hydration and prophylactic pancreatic duct stenting in high-risk cases also lower PEP incidence.\n\nNitroglycerin, a smooth muscle relaxant acting via nitric oxide-mediated sphincter relaxation, has shown promise in PEP prevention, especially in patients contraindicated for NSAIDs. Clinical trials indicate that transdermal or sublingual nitroglycerin reduces PEP rates, and combined use with NSAIDs may enhance protection. However, current guidelines do not routinely recommend nitroglycerin due to limited consensus on its efficacy.\n\nTopical nitroglycerin, known to relax smooth muscles locally and used in anorectal conditions, might reduce sphincter of Oddi pressure without systemic side effects. This suggests potential benefit in lowering PEP incidence or severity when applied topically during ERCP, pending further investigation. This study aimed to investigate whether topical delivery of nitroglycerin can reduce the incidence rate of PEP or the severity of pancreatitis.",[317],"Pancreatitis",[319,320],"post-ERCP pancreatitis","nitroglycerin",{"date":322,"type":35},"2025-12-08",{"date":324,"type":35},"2025-09-15",{"date":326,"type":20},"2027-07-31",{"name":40,"class":41},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":16,"minAge":98,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":21,"phases":337,"briefSummary":338,"conditions":339,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":347,"locationsCount":89},"100612472","precision-health-and-smart-telerehabilitation-in-osa-100612472","NCT07254026","Precision Health and Smart Telerehabilitation in OSA","Developing a Precision Health Approach for Obstructive Sleep Apnea: Treatment Responses Analysis and Smart Telerehabilitation Systems","Inclusion Criteria:\n\n* 20 years old and above\n* Newly diagnosed with mild to severe pure obstructive sleep apnea based on polysomnography\n\nExclusion Criteria:\n\n* Severe allergic rhinitis\n* Sinusitis with nasal polyps\n* Body Mass Index (BMI) \\> 31\n* Alcohol or drug abuse within the past year\n* Pregnancy\n* Severe obstructive or restrictive pulmonary diseases\n* High-risk cardiovascular diseases during exercise (e.g., angina, myocardial infarction, heart failure, valvular heart disease)\n* History of central or peripheral neurological disorders that interfere with exercise prescription\n* Musculoskeletal or psychological disorders that interfere with exercise prescription\n* Other non-respiratory sleep disorders\n* Sleep disorders with concomitant central sleep apnea",{"count":336,"type":20},300,[23],"This study aims to improve treatment strategies for Obstructive Sleep Apnea (OSA), a disorder characterized by recurrent upper airway collapse during sleep, resulting in reduced oxygenation, sleep fragmentation, and excessive daytime sleepiness. The objectives are twofold: to evaluate whether an artificial intelligence (AI)-based model can accurately predict the most effective treatment for individual patients, and to assess whether a mobile health application can enhance adherence to oropharyngeal rehabilitation (OPR) and improve therapeutic outcomes.\n\nThe study will be conducted in two phases. In Phase I, a retrospective analysis will be performed using a large dataset of polysomnography (PSG) records obtained from the Sleep Center at National Cheng Kung University Hospital. Machine learning algorithms will be applied to identify predictive features that differentiate responders from non-responders across Continuous Positive Airway Pressure (CPAP), surgical, and OPR interventions. These findings will inform the development of a predictive treatment recommendation model.\n\nIn Phase II, a prospective clinical trial will validate the predictive accuracy and clinical utility of the model. Patients newly diagnosed with OSA will be assigned to CPAP, surgery, or OPR interventions according to the model's recommendations, in combination with physician judgment and patient preference. Each intervention will last 12 weeks, followed by repeat PSG and clinical assessments. Within the OPR arm, participants will be further randomized to monitor adherence via an exercise diary or a smartphone application equipped with a pressure sensor and facial motion recognition technology, enabling real-time feedback and remote monitoring.\n\nThis trial is expected to determine whether AI can provide clinically reliable treatment recommendations and whether digital telerehabilitation can improve adherence and outcomes, thereby advancing precision medicine in OSA management.",[340],"Obstructive Sleep Apnea","2025-11-19",{"date":343,"type":35},"2025-11-28",{"date":345,"type":35},"2025-10-15",{"date":87,"type":20},{"name":40,"class":41},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":355,"minAge":356,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":21,"phases":359,"briefSummary":360,"conditions":361,"keywords":364,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":89},"100611626","ultrasound-and-electromyography-biofeedback-for-pelvic-floor-muscle-training-100611626","NCT07243028","Ultrasound and Electromyography Biofeedback for Pelvic Floor Muscle Training","Application of Simultaneous Pelvic Floor Ultrasonography and Electromyography Biofeedback on Pelvic Floor Muscle Training","Inclusion Criteria:\n\n1. Women aged 21 years or older diagnosed with pelvic floor muscle dysfunction and requiring pelvic floor muscle training (e.g., for symptomatic pelvic organ prolapse, stress urinary incontinence, or dysfunctional voiding).\n2. A Pelvic Floor Disability Index (PFDI-20) score greater than 1.\n3. Ability and willingness to provide written informed consent and authorization for the release of personal health information.\n4. Willingness and ability to complete all required questionnaires\n\nExclusion Criteria:\n\n1. Individuals planning a future pregnancy.\n2. Inability to read, understand, or sign the written consent form prior to participation.","FEMALE","21 Years",{"count":358,"type":20},70,[23],"This study aims to investigate the factors influencing adherence to pelvic floor muscle training (PFMT) devices among patients with pelvic floor dysfunction (PFD) through structured questionnaires, while simultaneously comparing the effectiveness of different feedback modalities, including non-invasive ultrasound imaging and invasive manometry with electromyography (EMG). By integrating subjective adherence data with objective performance outcomes, the project seeks to evaluate the potential of system-level integration for personalized therapeutic strategies, ultimately enhancing treatment efficacy, improving patient satisfaction, and promoting sustained engagement in PFMT.",[362,363],"Pelvic Floor Dysfunction","Pelvic Floor Muscle Weakness",[365,366,367,368],"Pelvic floor dysfunction","Pelvic floor muscle training","Health behavior","Biofeedback",{"date":370,"type":35},"2025-11-21",{"date":372,"type":35},"2024-02-29",{"date":374,"type":20},"2028-12-31",{"name":40,"class":41},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":97,"sex":355,"minAge":17,"maxAge":99,"enrollmentInfo":383,"targetDuration":4,"studyType":21,"phases":385,"briefSummary":386,"conditions":387,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":394,"locationsCount":89},"100604061","investigating-the-correlation-between-pre-treatment-imaging-derived-body-composition-chemotherapy-dose-adjustment-and-treatment-efficacy-in-gynecological-cancer-patients--100604061","NCT07144618","Investigating the Correlation Between Pre-Treatment Imaging-Derived Body Composition, Chemotherapy Dose Adjustment, and Treatment Efficacy in Gynecological Cancer Patients \"","A Multicenter Ambidirectional Study Investigating the Association Between Pre-Treatment Imaging-Derived Body Composition, Chemotherapy Dose Adjustment, and Treatment Efficacy in Patients With Endometrial and Ovarian Cancer","Inclusion Criteria\n\n1. Able to comprehend and willing to participate in this clinical trial, with signed informed consent.\n2. Underwent an abdominal computed tomography (CT) scan within three months prior to surgical treatment, with a non-contrast-enhanced single-slice image at the third lumbar vertebral level available for body composition analysis.\n3. Histologically or cytologically confirmed diagnosis of endometrial cancer or ovarian cancer.\n4. Age between 20 and 80 years.\n5. Good performance status (ECOG performance status of 0, 1, or 2).\n6. Adequate hematologic parameters:\n\n   * Hemoglobin ≥10 g\u002FdL\n   * White blood cell count ≥3,000\u002FμL\n   * Neutrophil count ≥1,500\u002FμL\n   * Platelet count ≥100,000\u002FμL\n7. Adequate organ function:\n\n   * Total bilirubin ≤1.5 times the upper limit of normal (ULN).\n   * Alanine aminotransferase (ALT) \u002F Aspartate aminotransferase (AST) ≤2.5 times ULN (≤5.0 times ULN for patients with liver metastases).\n   * Creatinine ≤ ULN. Exclusion Criteria\n\n1\\. Presence of other major diseases that may be exacerbated by chemotherapy (e.g., autoimmune diseases).\n\n2\\. History of other malignancies within the past two years before trial enrollment, except for adequately treated non-melanoma skin cancer, stage 0 cervical carcinoma, or ductal carcinoma in situ of the breast.\n\n3\\. Requirement for concurrent treatment of unrelated diseases during the trial period, including chemotherapy, radiotherapy, or investigational drugs.\n\n4\\. Mental status deemed unsuitable for participation in the clinical trial. 5. Expected survival time of less than six months. 6. Poor-quality abdominal CT images, clearly attributable to the following causes:\n\n* Motion artifacts due to poor patient compliance.\n* Noticeable scoliosis or kyphosis.\n* Multiple lumbar vertebral compression fractures.\n* Significant generalized edema.\n* Presence of metallic implants in the lumbar spine or abdomen.\n* Abdominal stoma or significant abdominal wall defects.\n* Marked asymmetry or localized atrophy\u002Fdeficiency of the core abdominal musculature.",{"count":384,"type":20},294,[23],"The dosage of paclitaxel, an adjuvant chemotherapy agent for endometrial and ovarian cancer, is typically calculated based on the patient's body surface area (BSA). However, cancer patients with the same BSA may exhibit significant differences in body composition, which could influence the distribution pattern of paclitaxel in the body. These variations may lead to individual differences in drug tolerance and adverse effects. Such variability not only impacts the patient's treatment experience and quality of life but may also increase medical costs, including hospitalization, emergency department visits, and additional treatments required to manage chemotherapy-induced toxicities.\n\nOur preliminary study results indicate that skeletal muscle area (SMA) and skeletal muscle index (SMI), as assessed through computed tomography (CT) imaging, are significantly associated with the incidence of Grade 3 or higher leukopenia or neutropenia following the first two cycles of chemotherapy in patients with endometrial cancer. Furthermore, the predictive accuracy of these CT-derived muscle measurements surpasses the clinical judgment made by physicians based on conventional treatment guidelines. Patients who develop Grade 3 or higher leukopenia or neutropenia during the first two cycles are more likely to experience more frequent occurrences of Grade 3 or higher chemotherapy-related adverse effects in subsequent treatment cycles.\n\nHowever, no study has comprehensively investigated the relationship between body composition, chemotherapy dosing, and adverse effects. Therefore, this trial aims to examine the impact of body composition on chemotherapy dose adjustments and adverse effects. By utilizing body composition data extracted from abdominal CT imaging through this product, this study seeks to establish a risk stratification tool to assist physicians in treating patients with endometrial and ovarian cancer by providing a reference for chemotherapy dose reduction.\n\nIt is expected that through a precision chemotherapy strategy, the incidence of chemotherapy-related adverse effects can be reduced, thereby lowering medical resource expenditures incurred from managing these adverse effects, such as emergency department visits, hospitalizations, additional diagnostic tests, and supportive medication costs. Furthermore, this approach aims to improve patients' health-related quality of life and achieve a dual benefit of medical economic efficiency and clinical effectiveness.",[388],"Search MeSH",{"date":390,"type":35},"2025-09-22",{"date":392,"type":20},"2025-09",{"date":374,"type":20},{"name":40,"class":41},{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":402,"enrollmentInfo":403,"targetDuration":4,"studyType":21,"phases":405,"briefSummary":407,"conditions":408,"keywords":410,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":89},"100556924","phase-1-establishing-best-treatment-strategy-for-t4-esophageal-cancer-100556924","NCT06531434","Establishing Best Treatment Strategy for T4 Esophageal Cancer","A Pilot Study to Establish Best Treatment Strategy for T4 Esophageal Cancer","Inclusion Criteria:\n\n1. Histologically confirmed esophageal squamous cell carcinoma\n2. Tumor or lymph nodes invade adjacent organs (T4 stage)\n3. Aged between 18-70 years old\n4. Patient health status score Eastern Cooperative Oncology Group (ECOG) performance status (PS) \\\u003C2\n5. Hemoglobin ≥ 10 g\u002FL, absolute neutrophil count ≥ 2×10\\^3\u002FL, platelet count ≥ 100×10\\^9\u002FL, total bilirubin ≤ 1.5 mg\u002FL, serum transaminases ≤ 105 U\u002FL, creatinine clearance ≥ 40 mL\u002Fmin.\n\nExclusion Criteria:\n\n1. Previous chemotherapy history\n2. Myocardial infarction within the last three months\n3. History of unstable angina, interstitial pneumonia, fibrotic lung disease, or severe emphysema\n4. Has other malignancies currently\n5. Uncontrolled infection\n6. Pregnancy or lactation\n7. Perforated esophagus at the time of diagnosis","70 Years",{"count":404,"type":20},22,[406,128],"PHASE1","The goal of this clinical trial is to investigate the safety and efficacy of a new treatment approach for T4-stage esophageal cancer, which involves chemoradiotherapy after induction chemotherapy. The main questions it aims to answer are:\n\n* Does the new induction chemotherapy followed by chemoradiation reduce esophageal perforation rate?\n* Does the new induction chemotherapy followed by chemoradiation increase treatment response rate and patient survival? Researchers will analyze the above data to see if the new treatment approach works to treat T4 esophageal cancer.\n\nParticipants will:\n\n* Receive induction chemotherapy for 4 to 8 cycles, followed by chemoradiation therapy if downstage to T3\n* Visit the clinic once every week for checkups and tests\n* Keep a diary of their symptoms",[409],"Esophageal Cancer TNM Staging Primary Tumor (T) T4",[411,412],"T4 esophageal cancer","Induction chemotherapy",{"date":390,"type":35},{"date":415,"type":35},"2024-08-01",{"date":417,"type":20},"2026-04-30",{"name":40,"class":41},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":97,"sex":16,"minAge":425,"maxAge":99,"enrollmentInfo":426,"targetDuration":4,"studyType":21,"phases":428,"briefSummary":429,"conditions":430,"keywords":432,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":89},"100598897","innovative-hand-rehabilitation-system-with-synchronized-contralateral-haptic-feedback-100598897","NCT07077460","Innovative Hand Rehabilitation System With Synchronized Contralateral Haptic Feedback","Inclusion Criteria:\n\n* Age ranged from 20-80 years old\n* Without past medical history of musculoskeletal or neurological disorders that would affect muscle control ability or cause sensory abnormalities\n* Normal cognitive function to understand and follow the instructions\n* Able to understand Chinese, English, or Taiwanese language\n\nExclusion Criteria:\n\n* With a history of hand-related surgeries\n* With a history of neuromuscular diseases or degenerative arthritis\n* With a history of brain injury\n* With a history of taking psychiatric medications\n* Unable to understand instructions, or have cognitive impairments\n* With a history of physical disabilities (Loss of body parts) or taking relevant medications, including heart disease, peripheral arterial disease, respiratory system diseases, dialysis, unresolved upper extremity injury, or highly addicted to smoking or alcohol","60 Years",{"count":427,"type":20},100,[23],"Previous studies have found that graded motor imagery (GMI) training can provide continuous activation of the cerebral cortex compared to traditional rehabilitation therapy. One of the steps in this strategy, mirror therapy, has also been widely used in the clinical treatment of hemiplegic patients. Also, comparing with traditional rehabilitation treatments, mirror therapy can continuously provide cortical activation. Besides, several studies indicated that game-based interventions contribute to brain activation in the elderly due to their interest can improve users' motivation in the training program execution. In addition, force control training has positive effects on hand dexterity, and specific doses of motor control training not only improve motor function but also have positive effects on brain function.\n\nCurrently, hand function training primarily focuses on range of motion, strength, and hand function, although there is comparatively less emphasis on enhancing both force control and brain function. Moreover, studies related to mirror therapy has primarily focused on the execution of functional movements, but has not explored whether hand strength control training can achieve the same training effects on the affected or non-dominant side through the concept of mirror therapy. Furthermore, the effects of combining a hand strength control system with a synchronous contralateral clip-on force feedback device on brain activation and hand function have not yet been studied. Therefore, this study aimed to investigate the effects of integration a finger force control training system with synchronous contralateral force feedback and mirror visual feedback device on brain activation and hand function, aiming to develop a clinically applicable hand rehabilitation system. Additionally, visual feedback from force control training in our study is through the hints displayed virtually on the game interface of the tablet, which were represented as the height of the targets, not as typical as actual movement-based mirror therapy or task-based mirror therapy.\n\nTherefore, the purpose of the study is to understand the differences among training effects of integrating Graded-Pressure Haptic Device-TiPR closed-loop system and MVF; MVF and force control training, as well as isolated force control training, and to explore the training effects on hand strength, hand function and brain activation.",[431],"Healthy Elderly",[433,434,435,436,437,438],"Functional near infrared spectroscopy","Parameters of digit force independence","Mirror Visual Feedback","Hand Training System","Hand Dexterity","Synchronized contralateral haptic feedback","2025-08-24",{"date":441,"type":35},"2025-08-29",{"date":443,"type":35},"2024-10-04",{"date":445,"type":20},"2025-10-22",{"name":40,"class":41},{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":97,"sex":16,"minAge":17,"maxAge":69,"enrollmentInfo":454,"targetDuration":4,"studyType":21,"phases":456,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":89},"100527735","a-novel-multisensory-rhythmic-intervention-in-geriatric-rehabilitation-100527735","NCT06151626","A Novel Multisensory-Rhythmic Intervention in Geriatric Rehabilitation","Linking From an Artificial-Intelligence Driven Assessment of Upper Extremity Motor Adaptation to a Novel Multisensory-Rhythmic Intervention in Geriatric Rehabilitation","Inclusion Criteria:\n\n1. Montreal Cognitive Assessment (MoCA) score of 23 or higher,\n2. Clinical Dementia Rating (CDR) of 0 (for normal subjects) or 1 (for mild cognitive impairment subjects),\n3. Healthy young participants aged between 20-39 years, healthy older adults and mild cognitive impairment participants aged between 65-85 years,\n4. No skeletal, muscular, or neurological problems in the upper limbs in the past year, and\n5. Sufficient visual acuity to complete the tasks.\n\nExclusion Criteria:\n\n* Any subjects with significant mental illness, central nervous system disorders, or medical history",{"count":455,"type":20},108,[23],"Human performance takes shape from the dynamic interaction between person, environment, and task. Goal-directed action is a complex task, which requires the elderly to adapt their motor response according to the environment constraints and task requirements to accomplish the task goal. Among age-related problems, motor control deficits are often the main problems which restricts the frail elderly from maintaining independence for activities of daily living. Therefore, to preserve the quality of life, motor function of the elderly must be taken into consideration, including early detection of motor control problems and development of appropriate intervention strategy for persons with either healthy or pathological brain aging. Rhythmic skill training which is a new mode of dual tasks using rhythmic cueing as an external agent for facilitating an automatized motor task. During training, rhythmic skill training can provide multi-component of sensory stimulation, strengthen motor planning and optimize motor execution, therefore, it will improve the motor performance for the elderly or patients with mild cognitive impairment. In addition, the neuroplastic changes related to sensory processing, selective attention, or working memory demands through music rhythm training can facilitate the cognitive function for the elderly which is a current trend of geriatric rehabilitation. Moreover, the advantage of virtual reality is that it provides important information related to knowledge of result, which can induce better motor and cognitive training effects. Therefore, this research project will focus on assessing and intervening motor adaptation of upper extremity for the healthy elderly and patients with mild cognitive impairment. The first purpose of the project will analyze the difference in efficiency of responsive and predictive grasping motor adaptation among the healthy young adults, healthy elderly and patients with mild cognitive impairment through a test of perturbation-based of pinch-holding-up-activity, and use artificial intelligence for more accurate classification for the grasp pattern of healthy young adults, elderly and patients with mild cognitive impairment. The second one is to verify the effects of virtual-reality based rhythmic skill training system on the motor adaptation capability of upper limb and cognition for the elderly and patients with mild cognitive impairment.",[77,459,460,461],"Hand Mirror","Geriatric","Kinesiology, Applied","2025-08-15",{"date":464,"type":35},"2025-08-21",{"date":466,"type":35},"2023-12-05",{"date":468,"type":20},"2026-12",{"name":40,"class":41},{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":476,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":16,"minAge":98,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":21,"phases":480,"briefSummary":481,"conditions":482,"keywords":485,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":496,"locationsCount":89},"100602071","ahcc-as-immune-modulator-in-cancer-patients-treated-with-immunotherapy-100602071","NCT07118735","AHCC® as Immune Modulator in Cancer Patients Treated With Immunotherapy","A Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) as Immune Modulator in Cancer Patients Treated With Immunotherapy: a Phase 2 Double-blind, Randomized, Placebo-controlled Trial","NCKUH","Inclusion Criteria:\n\n* 1.Liver cancer patient who will receive immunotherapy\n* 2.At least one measurable tumor, according to RECIST version 1.1, that has not been treated with any local procedure.\n* 3.Age \\>=20 years old.\n* 4.ECOG performance status 0 or 1.\n* 5.White blood count \\>=2,000\u002Fmicroliter ; platelet count \\>=60,000\u002Fmicroliter.\n* 6.Liver transaminases (ALT and AST) \\\u003C=5 times upper limit of normal values (ULN); total bilirubin \\\u003C= 2 times ULN; creatinine clearance or eGFR \\> 50 mL\u002Fmin (either Cockcroft-Gault or MDRD is acceptable, whichever is higher).\n* 7.Subjects with chronic hepatitis B virus infection (HBV surface antigen (HBsAg) positive) must start antiviral therapy with nucleoside analogs (e.g., entecavir or tenofovir, according to current practice guidelines) before start of study drug treatment.\n\nExclusion Criteria:\n\n* 1.Major systemic diseases that the investigator considers inappropriate for participation.\n* 2.Any active autoimmune disease or history of known autoimmune disease except for vitiligo, resolved childhood asthma\u002Fatopy, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.\n* 3.Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol.\n* 4.Prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody (or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways).\n* 5.Requirement of systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses \\> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.\n* 6.Prior organ allograft or allogeneic bone marrow transplantation.\n* 7.Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation and in the judgment of the investigator would make the patient inappropriate for entry into this study.",{"count":479,"type":20},94,[23],"This is a prospective, double-blind, randomized, placebo-controlled trial to evaluate whether AHCC® (Active Hexose Correlated Compound) can enhance the effect of immunotherapy in liver cancer patients.",[483,484],"Liver Cancer","Hepatocellular Carcinoma",[486,487,488,489],"AHCC® (Active Hexose Correlated Compound)","immunotherapy","liver cancer","functional food","2025-08-07",{"date":492,"type":35},"2025-08-12",{"date":494,"type":20},"2025-08-20",{"date":374,"type":20},{"name":40,"class":41},{"id":498,"slug":499,"hasResults":12,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":4,"eligibilityCriteria":503,"healthyVolunteers":12,"sex":16,"minAge":98,"maxAge":504,"enrollmentInfo":505,"targetDuration":4,"studyType":21,"phases":507,"briefSummary":508,"conditions":509,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":89},"100496084","comprehensive-respiratory-training-exercise-program-in-obstructive-sleep-apnea-100496084","NCT05739617","Comprehensive Respiratory Training Exercise Program in Obstructive Sleep Apnea","Combining Sonography to Explore the Therapeutic Effect and Mechanism of a Comprehensive Respiratory Training Exercise Program on Cardiorespiratory Endurance and Airway Muscle Function in Obstructive Sleep Apnea","Inclusion Criteria:\n\n* Newly diagnosed with OSA (AHI≥ 5 events per hour)\n* Age between 20 to 65 years old\n* BMI of 18-30 kg.m-2\n\nExclusion Criteria: Diagnosed with any of the following diseases below:\n\n* Central or mixed types of sleep apnea\n* Neuromuscular disease\n* Severe cardiovascular disease\n* Active psychiatric disease\n* Head or neck disease or cancer\n* Structural abnormalities over the upper respiratory airway\n* Performed any operation or treatment over the neck before\n* Pregnancy","65 Years",{"count":506,"type":20},150,[23],"Obstructive sleep apnea (OSA) is a multi-factorial sleep disorder. Complete collapse or partial collapse in the airway increases the risk of developing cardiovascular and kidney-related disease in OSA patients. Resulting in an increase in medical expenses and workload for the healthcare worker. Multilevel of upper airway muscles especially the genioglossus muscle showed to contribute to airway obstruction as it fatigues easily. The endurance level of OSA patients was shown to be significantly lower. Therefore, the goal of this experimental study is to assess the feasibility and effectiveness of a comprehensive respiratory training exercise program on cardiorespiratory endurance, airway muscle function, and sleep parameters in patients with obstructive sleep apnea (OSA). Aside from exploring the therapeutic effect, the results of the study will be used to explore the mechanism of the treatment in relation to the changes in the OSA severity.",[510],"Obstructive Sleep Apnea of Adult","2025-06-15",{"date":513,"type":35},"2025-06-18",{"date":515,"type":35},"2023-03-01",{"date":517,"type":20},"2026-07-16",{"name":40,"class":41},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":21,"phases":528,"briefSummary":529,"conditions":530,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":4},"100591597","comparing-two-methods-to-measure-nasogastric-tube-length-100591597","NCT06982495","Comparing Two Methods to Measure Nasogastric Tube Length","Comparing Two Methods for Estimating Nasogastric Tube Length: A Randomized Control Study","Inclusion Criteria:\n\n* Adults (aged ≥18 years)\n* Patients requiring nasogastric tube placement\n* Patients who are hospitalized\n\nExclusion Criteria:\n\n* Patients with a chest wound that prevents palpation of the xiphoid process\n* Patients who have had a gastrectomy\n* Patients with a gastric tumor\n* Patients with a head and neck tumor\n* Patients who are agitated and difficult to place the nasogastric tube\n* Patients with abnormal esophageal structure\n* Patients with a basilar skull fracture\n* Patients with acute upper gastrointestinal bleeding\n* Patients with an expected lifespan of less than 48 hours\n* Patients who cannot undergo an X-ray confirmation (e.g., pregnant women)\n* Patients with unstable blood pressure (mean arterial pressure \\\u003C 65 mmHg)\n* Patients with ischemic, perforated, or obstructed bowel\n* Patients with high-output fistula\u002Fostomy\n* Patients using photosensitive drugs\n* Critically ill patients\n* Patients with acute needs as determined by the attending physician\n* Patients with a Glasgow Coma Scale score \\\u003C 8",{"count":527,"type":20},220,[23],"The goal of this clinical trial is to learn if using a novel nasogastric tube assisted placement system (NCKU-NG system) can more accurately place the nasogastric tube at the optimal position in the stomach compared to conventional blind insertion techniques in adult inpatients requiring nasogastric tube placement. The main questions it aims to answer are:\n\n* Does the NCKU-NG system improve the accuracy of nasogastric tube placement at the optimal gastric position compared to standard blind insertion?\n* Does the NCKU-NG system reduce the rate of misplacement (such as entry into the airway or inadequate gastric depth), number of repeated attempts, and complication rate compared to the conventional method?\n* Can estimation of nasogastric tube length using the NCKU-NG system provide a more reliable reference than external measurement or X-ray?\n\nResearchers will compare patients randomized to nasogastric tube insertion with the NCKU-NG system (intervention arm) versus conventional blind insertion following standard external measurement methods (control arm) to see if the NCKU-NG system improves placement accuracy and reduces adverse events.\n\nParticipants will:\n\n* Be randomized to one of two groups:\n\n  * Intervention group: Receive nasogastric tube insertion using the NCKU-NG system (video-assisted real-time visualization, with active confirmation of passage through the esophagogastric junction and final position in the stomach based on sidehole location).\n  * Control group: Receive traditional nasogastric tube blind bedside insertion based on standard measurement (eg. Nose-Earlobe-Xiphoid + 10 cm).\n* All procedures will use the same material nasogastric tube (16 French polyurethane radiopaque tube).\n* Undergo confirmation of tube position by X-ray within 8 hours post-insertion for both groups.\n* Have the following outcomes assessed:\n\n  * Placement accuracy (percentage of tubes placed at optimal predefined gastric position)\n  * Number of placement attempts and failures\n  * Rate of inadvertent airway or inadequate placement\n  * Incidence of complications (e.g., aspiration, pneumothorax, gastrointestinal tract injury)\n  * Correlation between video-assisted measurement and X-ray estimation of intragastric length",[531,532,533,534,535],"Intubation, Nasogastric","Intubation Intraesophageal","Intubation Depth","Intubation Times","Intubation; Complication","2025-05-22",{"date":538,"type":35},"2025-05-29",{"date":540,"type":20},"2025-06",{"date":542,"type":20},"2025-12",{"name":40,"class":41},{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":4,"eligibilityCriteria":550,"healthyVolunteers":12,"sex":16,"minAge":98,"maxAge":551,"enrollmentInfo":552,"targetDuration":4,"studyType":21,"phases":554,"briefSummary":555,"conditions":556,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":560,"leadSponsor":561,"locationsCount":89},"100592923","device-assisted-oropharyngeal-rehabilitation-in-obstructive-sleep-apnea-patients-using-continuous-positive-airway-pressure-100592923","NCT06999746","Device-Assisted Oropharyngeal Rehabilitation in Obstructive Sleep Apnea Patients Using Continuous Positive Airway Pressure","Effectiveness of Using Force Sensing Resistor to Assist Oropharyngeal Rehabilitation in Patients With Obstructive Sleep Apnea Using Continuous Positive Airway Pressure","Inclusion Criteria:\n\n* Adults aged 20 to 68 years\n* Newly diagnosed with mild to severe pure obstructive sleep apnea based on polysomnography\n\nExclusion Criteria:\n\n* Severe allergic rhinitis\n* Sinusitis with nasal polyps\n* Adenoid hypertrophy\n* Bilateral tonsillar hypertrophy (Friedman grade ≥ III)\n* Lingual tonsil hypertrophy (Friedman grade ≥ III)\n* Body Mass Index (BMI) \\> 40\n* Alcohol or drug abuse within the past year\n* Pregnancy\n* Severe obstructive or restrictive pulmonary diseases\n* High-risk cardiovascular diseases during exercise (e.g., angina, myocardial infarction, heart failure, valvular heart disease)\n* History of central or peripheral neurological disorders that interfere with exercise prescription\n* Musculoskeletal or psychological disorders that interfere with exercise prescription\n* Other non-respiratory sleep disorders\n* Sleep disorders with concomitant central sleep apnea","68 Years",{"count":553,"type":20},200,[23],"The goal of this clinical trial is to evaluate the effectiveness of device-assisted oropharyngeal rehabilitation (OPR) in improving upper airway muscle function and reducing obstructive sleep apnea (OSA) severity in adult patients diagnosed with OSA who are receiving continuous positive airway pressure (CPAP) therapy.\n\nThe main questions it aims to answer are:\n\n1. Does combining OPR with CPAP increase upper airway space volume compared to using CPAP alone?\n2. Does OPR improve tongue muscle strength, and is this improvement associated with reduced CPAP pressure requirements?\n3. Do patients receiving OPR (alone or combined with CPAP) show greater improvements in OSA severity and clinical symptoms compared to those receiving CPAP alone or no intervention? Researchers will compare four groups-Control, OPR-only, CPAP-only, and CPAP + OPR-to see if device-assisted OPR enhances treatment outcomes beyond CPAP alone.\n\nParticipants will:\n\n1. Be randomly assigned to one of four groups (Control, OPR-only, CPAP-only, CPAP+OPR).\n2. Perform home-based OPR exercises (30-45 minutes\u002Fsession, 1-2 sessions\u002Fday, 3-5 days\u002Fweek for 3 months) in the OPR and CPAP+OPR groups.\n3. Have their exercise monitored using a strength sensor, with intensity adjusted every 2-4 weeks during hospital visits.\n4. Undergo assessments before and after the intervention, including:\n\n(1) Polysomnography for OSA severity, (2) CT and ultrasound for upper airway and tongue muscle structure, (3) Tongue muscle strength\u002Fendurance tests, (4) Sleep quality questionnaires, (5) CPAP usage and pressure reports.",[340],{"date":558,"type":35},"2025-05-31",{"date":511,"type":20},{"date":87,"type":20},{"name":40,"class":41},{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":568,"targetDuration":4,"studyType":21,"phases":570,"briefSummary":571,"conditions":572,"keywords":574,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":576,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":580,"locationsCount":89},"100537926","effectiveness-of-povidone-iodine-versus-chlorhexidine-gluconate-solutions-in-reducing-microbial-contamination-in-spinal-surgery-wounds-during-intraoperative-soaking-100537926","NCT06284174","Effectiveness of Povidone-Iodine Versus Chlorhexidine Gluconate Solutions in Reducing Microbial Contamination in Spinal Surgery Wounds During Intraoperative Soaking.","Inclusion Criteria:\n\n* Patients who were diagnosed with lumbar spinal stenosis need to undergo posterior lumbar decompression with fusion surgery.\n\nExclusion Criteria:\n\n* People who are allergic to disinfectants (Providine or CHG)\n* The surgical site has been operated before.\n* Patients under active infection status.",{"count":569,"type":20},105,[23],"This study aims to assess the efficacy of intraoperative wound irrigation with iodine-containing and chlorhexidine-containing solutions in reducing bacterial colonization during spine surgery, and to determine which solution is more effective. Additionally, we aim to evaluate any side effects associated with the use of these two antiseptic solutions for wound irrigation.",[573],"Spine Infection",[575],"Spine surgery, Providine-iodine, Chlorohexidine gluconate, surgical wound infection",{"date":538,"type":35},{"date":578,"type":35},"2021-01-01",{"date":558,"type":20},{"name":40,"class":41},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":4,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":588,"enrollmentInfo":589,"targetDuration":4,"studyType":21,"phases":591,"briefSummary":592,"conditions":593,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":89},"100524344","prevention-of-post-sphincterotomy-bleeding-100524344","NCT06107504","Prevention of Post-sphincterotomy Bleeding","Prevention of Post-sphincterotomy Bleeding by Endoscopic Tranexamic Acid and Sucralfate Administration: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged ≥ 18 years who accept ERCP and sphincterotomy for common bile duct (CBD) stone extraction\n\nExclusion Criteria:\n\n* Paitnets with no schedules for sphincterotomy\n* Paitnets with unsuccessful CBD cannulation\n* Patients with allergy to sucralfate","95 Years",{"count":590,"type":20},120,[23],"Background and Aim: Endoscopic retrograde cholangiopancreatography (ERCP) and sphincterotomy (EST) are standard treatments for choledocholithiasis. However, 10% of post-EST bleeding was reported. Currently, there are no effective methods or medications for the prevention of post-EST bleeding. This study aimed to investigate whether the local administration of TXA and sucralfate can reduce the post-EST bleeding event.\n\nMethods: This is a randomized clinical trial. Patients with choledocholithiasis scheduled for ERCP with EST at National Cheng Kung University Hospital and Siriraj Hospital were enrolled. The study will recruit 120 patients. After randomization, 60 patients will be classified into the intervention group and 60 into the control group. The participants will receive standard ERCP and EST for common bile duct stone removal. If immediate polypectomy bleeding occurs, the investigators will apply standard endoscopic therapy by either local injection of diluted epinephrine or heater probe coagulation. After then, the investigators will spray 2g of sucralfate powder and 1g of tranexamic acid through duodenoscopy precisely on the post-EST wound in the intervention group. All enrolled patients will be monitored for delayed bleeding for 14 days after the ERCP.",[594],"Post-ERCP Bleeding","2025-05-21",{"date":597,"type":35},"2025-05-25",{"date":599,"type":35},"2024-01-01",{"date":601,"type":20},"2025-07-31",{"name":40,"class":41},""]